The Treatment of Pediatric Epilepsy with Lacosamide in China: a Real-world study

Objective We report the real-world expertise of lacosamide in the treatment of pediatric epilepsy, including the experience of children under four years old. Methods A retrospective analysis of the safety and efficacy of lacosamide treatment for pediatric epilepsy was conducted, using descriptive statistics to analyze medication age, drug dosage, duration of treatment, seizure-free rate, adverse event incidence, and other relevant factors. Result A total of 356 cases were treated with lacosamide, of which 289 were aged four years and older, and 67 were younger than four years old. The doses were 4.8 ± 2.8 mg/kg/day and 6.1 ± 3.9 mg/kg/day ( P  = 0.0104) respectively, administered twice daily. Among the patients who received doses of 5 mg/kg/day or more, 88 out of 175 (50.29%) were seizure-free, while in the group receiving less than 5 mg/kg/day, 55 out of 181 (30.39%) were seizure-free. The group receiving doses of 5 mg/kg/day or more had a significantly higher seizure-free rate ( P  = 0.0123). The seizure-free rates were 42% and 36% for the two groups, respectively. Conclusion Earlier intervention with lacosamide is associated with a higher seizure-free rate. Results of lacosamide treatment demonstrate good efficacy and tolerability in Chinese children with epilepsy aged four years and younger.What this paper adds1. Real-world data on efficacy and safety under 4 years old.2. The curative effect is dose-related, and the curative effect is better than 5 mg per kilogram per day. Trail Registration : ChiCTR2300075115